Vistagen Therapeutics Inc (VSTA) 5.5000 $VSTA V
Post# of 273249
Posted On: 08/29/2016 7:14:06 PM
Vistagen Therapeutics Inc (VSTA) 5.5000 $VSTA
VistaGen Announces Nasdaq Listing and Pricing of $10.0 Million Public Offering
PR Newswire - Tue May 10, 6:36PM CDT
VistaGen Therapeutics, Inc. (OTCQB: VSTA) (VistaGen or the Company), a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative product candidates for patients with diseases and disorders involving the central nervous system (CNS), today announced its common stock will begin trading on The NASDAQ Capital Market under the symbol ''VTGN" on May 11, 2016. The Company also announced the pricing of its public offering of 2,352,942 shares of common stock and warrants to purchase up to 2,352,942 shares of common stock, at a combined price to the public of $4.25 for aggregate gross proceeds of approximately $10.0 million. The warrants will have an exercise price of $5.30, are exercisable immediately, and will have a term of five years. VistaGen has granted the underwriters a 45-day option to purchase up to 352,942 additional shares of common stock and/or warrants to purchase up to 352,942 additional shares to cover over-allotments, if any.
Nutrisystem (NTRI) Q1 Earnings, Revenues Top; '16 View Up
Zacks Equity Research - Zacks Investment Research - Wed May 04, 8:02AM CDT
Nutrisystem Inc. (NTRI) reported first-quarter 2016 adjusted earnings of 13 cents per share, which beat the Zacks Consensus Estimate by 6 cents.
CENT: 25.86 (-0.30), NTRI: 28.91 (+0.12), WMT: 71.40 (+0.26)
VistaGen Therapeutics Appoints Jerry Gin, Ph.D., MBA to its Board of Directors
PR Newswire - Wed Mar 30, 7:05AM CDT
VistaGen Therapeutics, Inc. (OTCQB: VSTA) (VistaGen or the Company), a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative product candidates for patients with diseases and disorders involving the central nervous system (CNS), today announced that it has appointed Jerry Gin, Ph.D., MBA to its Board of Directors. Dr. Gin has also been appointed as a member of the Company's Audit Committee.
VistaGen Therapeutics Bolsters Clinical and Regulatory Advisory Board with Appointments of Distinguished Key Opinion Leaders in Depression
PR Newswire - Tue Mar 22, 7:05AM CDT
VistaGen Therapeutics Inc. (OTCQB: VSTA) (VistaGen or the Company), a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative product candidates for patients with diseases and disorders involving the central nervous system (CNS), today announced that it has appointed Sanjay Mathew, M.D. and Thomas Laughren M.D. to the Company's Clinical and Regulatory Advisory Board to join its existing members, Gerard Sanacora, M.D., Ph.D. and Maurizio Fava, M.D. The Company also announced today the appointment of Dr. Fava as Chairman of this Board.
VistaGen Secures Exclusive Worldwide Commercial Rights to Three Proprietary Stem Cell Technologies from University Health Network
PR Newswire - Wed Dec 23, 6:53AM CST
VistaGen Therapeutics, Inc. (OTCQB: VSTA), a clinical-stage biopharmaceutical company committed to developing and commercializing novel medicines to treat depression, cancer and diseases and disorders involving the central nervous system, today announced that it has secured exclusive worldwide commercial rights to three patent-pending stem cell technologies from University Health Network (UHN), Canada's largest research hospital. The newly licensed technologies were discovered and developed by distinguished UHN researcher, Dr. Gordon Keller, Director of UHN's McEwen Centre for Regenerative Medicine (McEwen Centre), one of the world's leading centers for stem cell and regenerative medicine research, and relate to the development of stem cells into heart, liver and cartilage cells for multiple potential commercial applications, including drug rescue and regenerative therapies for heart disease, liver disease and osteoarthritis. VistaGen now holds a total of five licenses to stem cell technologies developed in collaboration with UHN, the McEwen Centre and Dr. Keller.
VistaGen Announces First Patient Dosed in NIH-Sponsored Phase 2A Study of Orally Available AV-101 in Major Depressive Disorder
PR Newswire - Tue Nov 03, 6:53AM CST
VistaGen Therapeutics, Inc. (OTCQB: VSTA), a clinical-stage biopharmaceutical company committed to developing and commercializing novel medicines to treat depression, cancer and diseases and disorders involving the central nervous system (CNS), today announced that the first patient has been dosed in a Phase 2A study of its orally available AV-101 in adult patients with treatment-resistant Major Depressive Disorder (MDD). The study is being fully funded by the U.S. National Institutes of Health (NIH), and is being conducted at the U.S. National Institutes of Mental Health (NIMH), under the direction of Principal Investigator, Carlos Zarate, Jr., M.D. Dr. Zarate is Chief, Section on the Neurobiology and Treatment of Mood Disorders and Chief of Experimental Therapeutics and Pathophysiology Branch (ETPB) at the NIMH, and Clinical Professor of Psychiatry and Behavioral Sciences at The George Washington University. VistaGen received clearance from the U.S. Food and Drug Administration (FDA) and the NIH to initiate the study in July 2015, after entering into a Cooperative Research and Development Agreement (CRADA) with the NIMH in February 2015.
Dr. Maurizio Fava, Internationally Renowned Expert in the Field of Depression, Joins VistaGen's Clinical and Scientific Advisory Board
PR Newswire - Wed Oct 07, 6:53AM CDT
VistaGen Therapeutics, Inc. (OTCQB: VSTA), a clinical-stage biopharmaceutical company committed to developing and commercializing novel medicines to treat depression, cancer and diseases and disorders involving the central nervous system (CNS), today announced that Maurizio Fava, MD, a world renowned expert in depressive disorders and psychopharmacology, has joined the Company's Clinical and Scientific Advisory Board, effective immediately. Dr. Fava is Director of the Division of Clinical Research of the Massachusetts General Hospital (MGH) Research Institute, Executive Vice Chair, Department of Psychiatry at MGH, and Executive Director of the MGH Clinical Trials Network and Institute (CTNI), as well as Slater Family Professor of Psychiatry at Harvard Medical School. He co-developed, with Dr. David Schoenfeld, Professor of Biostatistics at the Harvard School of Public Health, a novel, patented clinical trial design which increases the probability of detecting a positive drug response, while markedly reducing sample size requirements for the trial, by reducing the potentially high placebo response sometimes found in depression, and other, clinical trials.
Vista Receives coverage and issued significant U-P-G-R-A-D-D-E
M2 - Fri Jun 19, 10:19AM CDT
Companies mentioned in this article: Vistagen Therapeutics Inc (OTC: VSTA), Digital Ally (NASDAQ: DGLY), athenaHealth (NASDAQ: ATHN), Juno (NASDAQ: JUNO), Kite Pharma (NASDAQ: KITE) and Virgin America (NASDAQ: VA)
SIGM: 7.50 (-0.05), RAVE: 3.99 (unch), CHFN: 13.09 (-0.11), ABCO: 42.18 (+0.12), TI: 9.01 (-0.01), XXIA: 11.71 (-0.03), H: 54.05 (-0.03), ATHN: 122.89 (+0.80), VCRA: 16.48 (-0.23), IMPR: 19.18 (unch), VA: 55.86 (-0.11), VAR: 96.31 (+0.94), KITE: 58.04 (-0.60), CVS: 93.08 (-0.18), JUNO: 31.81 (-0.45), HMSY: 21.93 (+0.19), OMCL: 38.03 (+0.57), DGLY: 6.16 (+0.07), CERN: 65.00 (+0.36), PINC: 31.50 (+0.65), SHOR: 8.00 (+0.02)
Biotech ETFs open higher a day after hitting record highs
M2 - Fri Jun 19, 10:12AM CDT
Companies and ETFs mentioned in this article: Nasdaq Biotechnology ETF (NYSE: IBB), SPDR S&P Biotech ETF (NYSE: XBI), Gilead Sciences (NASDAQ: GILD), Vistagen Therapeutics Inc (OTC: VSTA), and Axovant Sciences (NYSE: AXON).
AXON: 16.61 (-0.08), GILD: 78.17 (-1.60), XBI: 61.04 (-0.06), IBB: 283.87 (-1.27)
Shopify's off and running
M2 - Thu May 21, 10:19AM CDT
Companies mentioned in this article: Shopify Inc. (SHOP), Banjo and Matilda (BANJ), Source Financial (SRCF), and VistaGen (VSTA)
SHOP: 41.39 (-0.13)
Follow the Gileader
M2 - Thu May 07, 8:26AM CDT
Companies mentioned in this article: Gilead Sciences (NASDAQ: GILD), Alexion Pharmaceuticals Inc. (NASDAQ: ALXN), Synageva BioPharma Corp. (NASDAQ: GEVA), VistaGen (OTCQB: VSTA), Juno Therapeutics, Inc. (JUNO) and Fate Therapeutics, Inc. (FATE)
GEVA: 238.60 (+2.80), GILD: 78.17 (-1.60), ALXN: 127.99 (-1.64), JUNO: 31.81 (-0.45)
Gilead Sciences Knocks it out of the Park, but does that mean that Biopharma is Undervalued?
M2 - Mon May 04, 7:40AM CDT
After taking a beating to close out April, with iShares Nasdaq Biotechnology (NASDAQ: IBB) losing nearly 10% off the mid-month highs, the biotech sector may have gotten the shot in the arm it need for the next leg up. By generating $2.94 a share profits, more than doubling the previous year's quarterly profits, on $7.6 billion revenues, a better than 50% improvement in year-over-year revenues, Gilead Sciences (NASDAQ: GILD) destroyed its earnings and 2015 sales guidance to the $28-29 billion range. By doing so, Gilead may have just kick started the next biopharma bull run.
GILD: 78.17 (-1.60), PFE: 35.11 (+0.29), IBB: 283.87 (-1.27), GSK: 43.61 (+0.06), CAPN: 1.02 (-0.03)
BioPharmas are running the FDA Fast Track to Success
M2 - Wed Apr 22, 4:06AM CDT
Biopharma listings tend to reward investors early and often. One of my favorite plays in this sector is the 505(b)(2), an FDA provision that's best known as the fast track announcement. Since these announcements are often made before the street is familiar with the company, or the developmental treatment, the biopharma premium is not priced into the listings. Fast Track designation may be awarded to medicines that are intended to treat a serious or life-threatening disease, or condition, and demonstrate the potential to address unmet medical needs. In addition to reducing the development and approval timeline, the provision can also reduce the financial outlay needed to commercialize the respective products.
HZNP: 18.84 (-0.59), ABIO: 2.98 (+0.13), ORPN: 1.66 (-0.05), DYAX: 38.04 (-0.37)
VistaGen and NIH Sign Agreement for NIH-Sponsored Phase 2 Study of Orally-Active AV-101 in Major Depressive Disorder
Marketwired - Tue Feb 17, 8:04AM CST
VistaGen Therapeutics, Inc. (OTCQB: VSTA), a clinical-stage biopharmaceutical company developing innovative medicine for depression and conditions involving the central nervous system (CNS), has entered into a Cooperative Research and Development Agreement (CRADA) with the U.S. National Institute of Mental Health (NIMH), part of the U.S. National Institutes of Health (NIH). Under the CRADA, VistaGen and the NIMH will collaborate on an NIH-sponsored Phase 2 clinical study of AV-101, VistaGen's orally-active NMDA receptor modulator, in subjects with Major Depressive Disorder (MDD). MDD is a widespread and debilitating mental disorder affecting millions worldwide, including nearly 7% of U.S. adults.
Dr. Gerard Sanacora Joins VistaGen's Clinical and Scientific Advisory Board
Marketwired - Thu Feb 05, 9:53AM CST
VistaGen Therapeutics, Inc. (OTCQB: VSTA), a clinical-stage biopharmaceutical company developing innovative medicine for depression and conditions involving the central nervous system, has added Gerard Sanacora PhD, MD, Professor of Psychiatry at the Yale School of Medicine and Director of the Yale Depression Research Program, to its Clinical and Scientific Advisory Board. Dr. Sanacora will focus on Phase 2 and Phase 3 clinical development of AV-101, VistaGen's orally-active NMDA receptor modulator for treating Major Depressive Disorder (MDD). AV-101 is a unique prodrug candidate that produces, in the brain, 7-chlorokynurenic acid (7-Cl-KYNA), one of the most potent and selective antagonists of the required glycine-binding site of the NMDA receptor, which results in down-regulation of NMDA signaling.
VistaGen Signs Letter of Intent With National Institute of Mental Health for NIH-Sponsored Phase 2 Clinical Study of AV-101 in Major Depressive Disorder
Marketwired - Wed Nov 19, 2:42PM CST
VistaGen Therapeutics, Inc. (OTCQB: VSTA), a clinical-stage biopharmaceutical company focused on innovative medicine for depression, cancer and diseases and disorders involving the central nervous system (CNS), has signed a Letter of Intent to enter into a Cooperative Research and Development Agreement (CRADA) with the National Institute of Mental Health (NIMH), part of the National Institutes of Health (NIH), to collaborate on a NIMH-sponsored Phase 2 clinical study of VistaGen's lead drug candidate, AV-101, in Major Depressive Disorder, one of the most common mental disorders in the U.S.
VistaGen Announces Nasdaq Listing and Pricing of $10.0 Million Public Offering
PR Newswire - Tue May 10, 6:36PM CDT
VistaGen Therapeutics, Inc. (OTCQB: VSTA) (VistaGen or the Company), a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative product candidates for patients with diseases and disorders involving the central nervous system (CNS), today announced its common stock will begin trading on The NASDAQ Capital Market under the symbol ''VTGN" on May 11, 2016. The Company also announced the pricing of its public offering of 2,352,942 shares of common stock and warrants to purchase up to 2,352,942 shares of common stock, at a combined price to the public of $4.25 for aggregate gross proceeds of approximately $10.0 million. The warrants will have an exercise price of $5.30, are exercisable immediately, and will have a term of five years. VistaGen has granted the underwriters a 45-day option to purchase up to 352,942 additional shares of common stock and/or warrants to purchase up to 352,942 additional shares to cover over-allotments, if any.
Nutrisystem (NTRI) Q1 Earnings, Revenues Top; '16 View Up
Zacks Equity Research - Zacks Investment Research - Wed May 04, 8:02AM CDT
Nutrisystem Inc. (NTRI) reported first-quarter 2016 adjusted earnings of 13 cents per share, which beat the Zacks Consensus Estimate by 6 cents.
CENT: 25.86 (-0.30), NTRI: 28.91 (+0.12), WMT: 71.40 (+0.26)
VistaGen Therapeutics Appoints Jerry Gin, Ph.D., MBA to its Board of Directors
PR Newswire - Wed Mar 30, 7:05AM CDT
VistaGen Therapeutics, Inc. (OTCQB: VSTA) (VistaGen or the Company), a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative product candidates for patients with diseases and disorders involving the central nervous system (CNS), today announced that it has appointed Jerry Gin, Ph.D., MBA to its Board of Directors. Dr. Gin has also been appointed as a member of the Company's Audit Committee.
VistaGen Therapeutics Bolsters Clinical and Regulatory Advisory Board with Appointments of Distinguished Key Opinion Leaders in Depression
PR Newswire - Tue Mar 22, 7:05AM CDT
VistaGen Therapeutics Inc. (OTCQB: VSTA) (VistaGen or the Company), a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative product candidates for patients with diseases and disorders involving the central nervous system (CNS), today announced that it has appointed Sanjay Mathew, M.D. and Thomas Laughren M.D. to the Company's Clinical and Regulatory Advisory Board to join its existing members, Gerard Sanacora, M.D., Ph.D. and Maurizio Fava, M.D. The Company also announced today the appointment of Dr. Fava as Chairman of this Board.
VistaGen Secures Exclusive Worldwide Commercial Rights to Three Proprietary Stem Cell Technologies from University Health Network
PR Newswire - Wed Dec 23, 6:53AM CST
VistaGen Therapeutics, Inc. (OTCQB: VSTA), a clinical-stage biopharmaceutical company committed to developing and commercializing novel medicines to treat depression, cancer and diseases and disorders involving the central nervous system, today announced that it has secured exclusive worldwide commercial rights to three patent-pending stem cell technologies from University Health Network (UHN), Canada's largest research hospital. The newly licensed technologies were discovered and developed by distinguished UHN researcher, Dr. Gordon Keller, Director of UHN's McEwen Centre for Regenerative Medicine (McEwen Centre), one of the world's leading centers for stem cell and regenerative medicine research, and relate to the development of stem cells into heart, liver and cartilage cells for multiple potential commercial applications, including drug rescue and regenerative therapies for heart disease, liver disease and osteoarthritis. VistaGen now holds a total of five licenses to stem cell technologies developed in collaboration with UHN, the McEwen Centre and Dr. Keller.
VistaGen Announces First Patient Dosed in NIH-Sponsored Phase 2A Study of Orally Available AV-101 in Major Depressive Disorder
PR Newswire - Tue Nov 03, 6:53AM CST
VistaGen Therapeutics, Inc. (OTCQB: VSTA), a clinical-stage biopharmaceutical company committed to developing and commercializing novel medicines to treat depression, cancer and diseases and disorders involving the central nervous system (CNS), today announced that the first patient has been dosed in a Phase 2A study of its orally available AV-101 in adult patients with treatment-resistant Major Depressive Disorder (MDD). The study is being fully funded by the U.S. National Institutes of Health (NIH), and is being conducted at the U.S. National Institutes of Mental Health (NIMH), under the direction of Principal Investigator, Carlos Zarate, Jr., M.D. Dr. Zarate is Chief, Section on the Neurobiology and Treatment of Mood Disorders and Chief of Experimental Therapeutics and Pathophysiology Branch (ETPB) at the NIMH, and Clinical Professor of Psychiatry and Behavioral Sciences at The George Washington University. VistaGen received clearance from the U.S. Food and Drug Administration (FDA) and the NIH to initiate the study in July 2015, after entering into a Cooperative Research and Development Agreement (CRADA) with the NIMH in February 2015.
Dr. Maurizio Fava, Internationally Renowned Expert in the Field of Depression, Joins VistaGen's Clinical and Scientific Advisory Board
PR Newswire - Wed Oct 07, 6:53AM CDT
VistaGen Therapeutics, Inc. (OTCQB: VSTA), a clinical-stage biopharmaceutical company committed to developing and commercializing novel medicines to treat depression, cancer and diseases and disorders involving the central nervous system (CNS), today announced that Maurizio Fava, MD, a world renowned expert in depressive disorders and psychopharmacology, has joined the Company's Clinical and Scientific Advisory Board, effective immediately. Dr. Fava is Director of the Division of Clinical Research of the Massachusetts General Hospital (MGH) Research Institute, Executive Vice Chair, Department of Psychiatry at MGH, and Executive Director of the MGH Clinical Trials Network and Institute (CTNI), as well as Slater Family Professor of Psychiatry at Harvard Medical School. He co-developed, with Dr. David Schoenfeld, Professor of Biostatistics at the Harvard School of Public Health, a novel, patented clinical trial design which increases the probability of detecting a positive drug response, while markedly reducing sample size requirements for the trial, by reducing the potentially high placebo response sometimes found in depression, and other, clinical trials.
Vista Receives coverage and issued significant U-P-G-R-A-D-D-E
M2 - Fri Jun 19, 10:19AM CDT
Companies mentioned in this article: Vistagen Therapeutics Inc (OTC: VSTA), Digital Ally (NASDAQ: DGLY), athenaHealth (NASDAQ: ATHN), Juno (NASDAQ: JUNO), Kite Pharma (NASDAQ: KITE) and Virgin America (NASDAQ: VA)
SIGM: 7.50 (-0.05), RAVE: 3.99 (unch), CHFN: 13.09 (-0.11), ABCO: 42.18 (+0.12), TI: 9.01 (-0.01), XXIA: 11.71 (-0.03), H: 54.05 (-0.03), ATHN: 122.89 (+0.80), VCRA: 16.48 (-0.23), IMPR: 19.18 (unch), VA: 55.86 (-0.11), VAR: 96.31 (+0.94), KITE: 58.04 (-0.60), CVS: 93.08 (-0.18), JUNO: 31.81 (-0.45), HMSY: 21.93 (+0.19), OMCL: 38.03 (+0.57), DGLY: 6.16 (+0.07), CERN: 65.00 (+0.36), PINC: 31.50 (+0.65), SHOR: 8.00 (+0.02)
Biotech ETFs open higher a day after hitting record highs
M2 - Fri Jun 19, 10:12AM CDT
Companies and ETFs mentioned in this article: Nasdaq Biotechnology ETF (NYSE: IBB), SPDR S&P Biotech ETF (NYSE: XBI), Gilead Sciences (NASDAQ: GILD), Vistagen Therapeutics Inc (OTC: VSTA), and Axovant Sciences (NYSE: AXON).
AXON: 16.61 (-0.08), GILD: 78.17 (-1.60), XBI: 61.04 (-0.06), IBB: 283.87 (-1.27)
Shopify's off and running
M2 - Thu May 21, 10:19AM CDT
Companies mentioned in this article: Shopify Inc. (SHOP), Banjo and Matilda (BANJ), Source Financial (SRCF), and VistaGen (VSTA)
SHOP: 41.39 (-0.13)
Follow the Gileader
M2 - Thu May 07, 8:26AM CDT
Companies mentioned in this article: Gilead Sciences (NASDAQ: GILD), Alexion Pharmaceuticals Inc. (NASDAQ: ALXN), Synageva BioPharma Corp. (NASDAQ: GEVA), VistaGen (OTCQB: VSTA), Juno Therapeutics, Inc. (JUNO) and Fate Therapeutics, Inc. (FATE)
GEVA: 238.60 (+2.80), GILD: 78.17 (-1.60), ALXN: 127.99 (-1.64), JUNO: 31.81 (-0.45)
Gilead Sciences Knocks it out of the Park, but does that mean that Biopharma is Undervalued?
M2 - Mon May 04, 7:40AM CDT
After taking a beating to close out April, with iShares Nasdaq Biotechnology (NASDAQ: IBB) losing nearly 10% off the mid-month highs, the biotech sector may have gotten the shot in the arm it need for the next leg up. By generating $2.94 a share profits, more than doubling the previous year's quarterly profits, on $7.6 billion revenues, a better than 50% improvement in year-over-year revenues, Gilead Sciences (NASDAQ: GILD) destroyed its earnings and 2015 sales guidance to the $28-29 billion range. By doing so, Gilead may have just kick started the next biopharma bull run.
GILD: 78.17 (-1.60), PFE: 35.11 (+0.29), IBB: 283.87 (-1.27), GSK: 43.61 (+0.06), CAPN: 1.02 (-0.03)
BioPharmas are running the FDA Fast Track to Success
M2 - Wed Apr 22, 4:06AM CDT
Biopharma listings tend to reward investors early and often. One of my favorite plays in this sector is the 505(b)(2), an FDA provision that's best known as the fast track announcement. Since these announcements are often made before the street is familiar with the company, or the developmental treatment, the biopharma premium is not priced into the listings. Fast Track designation may be awarded to medicines that are intended to treat a serious or life-threatening disease, or condition, and demonstrate the potential to address unmet medical needs. In addition to reducing the development and approval timeline, the provision can also reduce the financial outlay needed to commercialize the respective products.
HZNP: 18.84 (-0.59), ABIO: 2.98 (+0.13), ORPN: 1.66 (-0.05), DYAX: 38.04 (-0.37)
VistaGen and NIH Sign Agreement for NIH-Sponsored Phase 2 Study of Orally-Active AV-101 in Major Depressive Disorder
Marketwired - Tue Feb 17, 8:04AM CST
VistaGen Therapeutics, Inc. (OTCQB: VSTA), a clinical-stage biopharmaceutical company developing innovative medicine for depression and conditions involving the central nervous system (CNS), has entered into a Cooperative Research and Development Agreement (CRADA) with the U.S. National Institute of Mental Health (NIMH), part of the U.S. National Institutes of Health (NIH). Under the CRADA, VistaGen and the NIMH will collaborate on an NIH-sponsored Phase 2 clinical study of AV-101, VistaGen's orally-active NMDA receptor modulator, in subjects with Major Depressive Disorder (MDD). MDD is a widespread and debilitating mental disorder affecting millions worldwide, including nearly 7% of U.S. adults.
Dr. Gerard Sanacora Joins VistaGen's Clinical and Scientific Advisory Board
Marketwired - Thu Feb 05, 9:53AM CST
VistaGen Therapeutics, Inc. (OTCQB: VSTA), a clinical-stage biopharmaceutical company developing innovative medicine for depression and conditions involving the central nervous system, has added Gerard Sanacora PhD, MD, Professor of Psychiatry at the Yale School of Medicine and Director of the Yale Depression Research Program, to its Clinical and Scientific Advisory Board. Dr. Sanacora will focus on Phase 2 and Phase 3 clinical development of AV-101, VistaGen's orally-active NMDA receptor modulator for treating Major Depressive Disorder (MDD). AV-101 is a unique prodrug candidate that produces, in the brain, 7-chlorokynurenic acid (7-Cl-KYNA), one of the most potent and selective antagonists of the required glycine-binding site of the NMDA receptor, which results in down-regulation of NMDA signaling.
VistaGen Signs Letter of Intent With National Institute of Mental Health for NIH-Sponsored Phase 2 Clinical Study of AV-101 in Major Depressive Disorder
Marketwired - Wed Nov 19, 2:42PM CST
VistaGen Therapeutics, Inc. (OTCQB: VSTA), a clinical-stage biopharmaceutical company focused on innovative medicine for depression, cancer and diseases and disorders involving the central nervous system (CNS), has signed a Letter of Intent to enter into a Cooperative Research and Development Agreement (CRADA) with the National Institute of Mental Health (NIMH), part of the National Institutes of Health (NIH), to collaborate on a NIMH-sponsored Phase 2 clinical study of VistaGen's lead drug candidate, AV-101, in Major Depressive Disorder, one of the most common mental disorders in the U.S.
(0)
(0)Scroll down for more posts ▼